2011Freedom from Infectious Disease

ANNUAL REPORT

Hope starts here.

2

At various points in time, we’re provided the opportunity to celebrate both the past and the future at virtually the same moment. In 2011, Seattle BioMed had such an opportunity.

We celebrated our 35th anniversary – and 35 years of leadership by President and Founder Ken Stuart, Ph.D., a man who nurtured his vision into to a world-class center for infectious disease research – the first global health organization in a city whose name has become synonymous with improving the health of the world. To view a retrospective of Seattle BioMed’s history and understand how Ken’s vision has unfolded, please take a moment and visit seattlebiomed.org/history.

At the same time, a bold plan for scientific expansion and leadership for the future came to fruition. To enhance our research, particularly in the last couple years, we added various areas of expertise (such as immunology, early clinical and regulatory development) through strategic

LETTER FROM THE BOARD CHAIR

recruitment and expansion. We also began to explore the concept of applying a systems biology approach to infectious disease research, a truly revolutionary platform that has the potential to cut across and benefit all of our research programs.

Through a series of discussions with Alan Aderem, Ph.D., co-founder of the Institute for Systems Biology, the idea took shape. It was soon evident that Alan – a pioneer in the same vein as Ken – was the right choice to further expand our research and eventually succeed Ken as only the second president in the history of Seattle BioMed. As a native of South Africa, Alan has long been interested in global health, has seen firsthand the devastation of infectious diseases, and believes Seattle BioMed is the perfect place to meld his personal and professional goals.

From an organizational standpoint, Seattle BioMed will be incredibly fortunate as this transition occurs in January. Not only are we gaining Alan as President

to lead our efforts to integrate systems biology with infectious disease research, but we are retaining Ken in a new role as President Emeritus and Founder. We are so privileged to have two internationally renowned scientists in their respective fields in key roles at Seattle BioMed as we shape the next 35 years.

Imagine what the world can be with new drugs and vaccines to combat infectious diseases – healthy, productive and full of hope. Thank you for your support of Seattle BioMed.

Todd Patrick Chair, Board of Trustees

Seattle BioMed was founded 35 years ago with the vision of providing solutions to global infectious diseases through research. This vision gives hope for those who have no voice and no way to lift themselves out of the suffering caused by these diseases. It also lays the foundation for a healthier world that benefits all of us. Today we are fully committed and more able than ever to deliver on our vision. We know that research provides the foundation for the solutions that are needed to combat the world’s deadliest diseases.

Global infectious diseases do not respect borders, which is increasingly the case as global travel and international business expand. The suffering and death that these diseases cause impacts each of us indirectly in many ways no matter where we live. The need for new solutions is greater than ever, but the good news is that we are making progress.

Throughout this annual report, you’ll see how we are moving forward in making our vision a reality through our research. You’ll read about new research projects,

LETTER FROM THE PRESIDENT

exciting discoveries and the people who are engaged in our mission, from students and researchers to donors and volunteers.

We are excited about our future. By integrating the platform of systems biology with our infectious disease research, we are yet again pioneering the way in global health. The addition of new expertise, technologies and research programs has expanded our ability to have interdisciplinary scientific teams exploring the interface between pathogens and the humans that they infect. We can more deeply understand the biological mechanisms and processes at the level of complexity that occurs in biological systems. This enables us to gain new knowledge at a faster rate by taking a more systematic and comprehensive approach. Most importantly, I believe this integration of systems biology and infectious disease research will speed new solutions to those who need it most.

We are most fortunate to have been joined by Alan Aderem, Ph.D., and many other scientists and staff this year.

I welcome and support Alan’s move into the role of President of Seattle BioMed at the beginning of 2012. I look forward as President Emeritus and Founder to more fully focus on research projects and share the knowledge I’ve gained from years of challenges and success in the burgeoning field of global health. I can’t think of a more exciting and stimulating future here at Seattle BioMed than being surrounded by some of the brightest and most compassionate people in the world.

We thank all of those who have assisted Seattle BioMed. We cannot accomplish our mission – and provide hope – without your help.

Ken Stuart, Ph.D. President & Founder

We believe hope starts with research. Seattle BioMed’s 2011 Annual Report takes a look at research that is pushing discovery forward. Throughout these stories, we also glimpse forward to what the fruits of our science will bear – healthy people and thriving communities.

To conduct this research, Seattle BioMed is calling upon its proven areas of expertise and knowledge – successful vaccine and immunology studies in animal models of malaria, the ability to grow human malaria parasites in mosquitoes for research and clinical studies, and its ability to develop genetically attenuated parasite strains for human trials.

From mice to men (and women)Through Kappe’s research, Seattle BioMed scientists have developed genetically attenuated whole parasite (GAP) vaccine strains that have proven successful in rodent malaria models and have moved into human studies, which show the validity of the approach. “In this new study, we will use genetically attenuated parasite strains as probes to determine whether host correlates of immunity can be identified during vaccination in mice,” Kappe explained. “These model vaccines provide an opportunity to discriminate biomarkers associated with complete, long-lasting protection from those associated with partial, short-lived or lack of protection.”

After Seattle BioMed announced its bold plan to integrate a systems biology approach with its infectious disease research, malaria researchers wasted no time in incorporating this new method. In the first study of its type in the malaria field, Seattle BioMed researchers are identifying biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity. The ability to predict is a hallmark of the systems biology approach.

With an $8.9 million grant from the Bill & Melinda Gates Foundation, Seattle BioMed’s Ruobing Wang, M.D., Ph.D., is leading the study with a team that includes Seattle BioMed’s Stefan Kappe, Ph.D., and Alan Aderem, Ph.D., along with Patrick Duffy, M.D., of the National Institutes of Health, Jonathan Derry, Ph.D., of Sage Bionetworks, and Xiaowu Liang, Ph.D., of Antigen Discovery Inc. (ADi). In August 2011, the project was touted by a scientific website as one of “21 scientific research projects starting this fall that could change the world,” citing the need for an effective vaccine to combat malaria.

Biomarkers key to vaccinesAccording to Wang, the goal of the study is to identify and validate biomarkers that correlate with vaccine-induced protective immunity against malaria infection. “In order to bring the burden of malaria under control – with the ultimate goal of eradicating the pathogens that cause disease – we know we need a highly efficacious anti-infection vaccine,” she explained. “But, without reliable biomarkers of anti-infection immunity, the development and testing of malaria vaccines is a slow and expensive process.” Biomarkers will be used for prediction and monitoring the vaccine efficacy in clinical trials and to select optimal vaccine candidates for development.

Researchers at Seattle BioMed will then apply the knowledge gained in mouse models to human studies. “Through studies conducted at Seattle BioMed’s Malaria Clinical Trials Center, we’ll evaluate whether biomarkers of protection identified in the rodent models will predict protective immunity in humans,” explained Wang.

Fast track to vaccinesApplying Aderem’s expertise in the field of systems biology to malaria research will be a key component of this project. Seattle BioMed researchers are employing network analysis of transcriptional responses to predict protection in both mice and humans to determine if they can find universal markers that will allow them to optimize vaccine candidates. According to Aderem, the power of systems biology lies in its capacity to predict the behavior of a

biological system. “If we have the ability to predict whether a vaccine candidate for malaria will work before it goes into large scale clinical trials, we could move away from today’s typical ‘trial and error’ method toward a more powerful predictive approach to vaccine discovery and development,” he said.

Through these integrated studies, Seattle BioMed researchers will deliver a set of candidate immune biomarkers associated with protection against malaria infection that can be used for monitoring vaccine efficacy. “This will facilitate future malaria vaccine trials with the ultimate goal of accelerating the development of a highly effective malaria vaccine that has the potential to save millions of lives,” said Wang.

Predictive power: revolutionizing malaria vaccine discovery

One could never understand the complexity of the Amazon by investigating a single tributary. Instead, study how the river interacts with the environment throughout the basin. Then, one starts to understand the networks and relationships that make an ecosystem thrive. Systems biologists apply the same principles to study how disease impacts complex systems.

Ruobing Wang, M.D., Ph.D., Alan Aderem, Ph.D., and Stefan Kappe, Ph.D. 43

More than 33 million people are living with HIV/AIDS worldwide. Researchers in Helen Horton’s Seattle BioMed lab hope that understanding why some HIV-infected individuals never progress to AIDS could lead to an effective vaccine.

Like many of her Seattle BioMed colleagues, Horton is motivated by two related objectives – her natural curiosity of how biological systems work and her belief that research provides the basis for much-needed solutions for deadly infectious diseases. After completing her postdoctoral studies, she spent time traveling in Africa – seeing first-hand the need to stop the deadly epidemic that was sweeping the continent. “I realized that researching HIV/AIDS was the most important contribution I could make,” she said.

And, she’s found another piece of the HIV/AIDS puzzle. As Horton draws on her white board, she explains that, for many years, HIV/AIDS researchers have known that a group of rare individuals infected with HIV – called long-term nonprogressors – are able to control the virus without antiretroviral therapy (these individuals either do not develop full-blown AIDS or take much longer to develop the disease), but the specific method of how that happens wasn’t known.

Helen Horton, Ph.D.

Helen Horton, Ph.D., stands at the white board in her office. Her face lights up as she draws an illustration to explain her latest research findings – reflecting the excitement of scientific discovery. Many times people assume that research ends in a “eureka” finding resulting in a full-blown solution, but more often research builds upon itself, filling in yet another small piece of the disease puzzle. And each step in that discovery process provides new hope.

A principal investigator at Seattle BioMed, Horton discovered a critical piece of information that adds new knowledge about HIV/AIDS, with far-reaching implications for both control of chronic infection and autoimmunity. Her findings were reported in the prestigious scientific journal Nature Medicine.

A critical piece of the HIV puzzle: solvedHer findings in Nature Medicine detail a previously unknown explanation for why long-term nonprogressors can control HIV infection.

The new information Horton discovered proves to be beneficial in chronic infections, like HIV, but detrimental in autoimmunity. “While we’ve learned a valuable piece of information we didn’t know before, this leads to more questions, which will be the next focus of my research,” said Horton.

5 6

Natural selection: finding future scientists and drug discoveries in our own backyard

When it comes to treating ailments, some of the best medicines are found in nature: White willow bark contains a chemical similar to aspirin. Quinine – one of the first effective malaria treatments – occurs in the bark of the cinchona tree. With drug resistance becoming more prevalent today, scientists are desperate to find new drugs to treat disease. Perhaps it’s only natural to turn an eye toward what grows in our own backyard.

Jessica Winkler did just that. A 2006 graduate of Seattle BioMed’s high school science education program BioQuest, Winkler is now continuing her training as an undergraduate intern in the tuberculosis research lab of David Sherman, Ph.D. She spent her summer paying forward the training she received by helping a local science teacher design an experiment that investigates the drug properties of Northwest plants.

Student becomes teacher“I had the opportunity to help Lindberg High School teacher Anna Dehn develop a research experiment that could be replicated and taught in her classroom setting,” said Winkler. “I knew the class would need access to common materials, and with so many plants having antimicrobial and antibiotic properties, I thought: ‘Why not use them in a drug discovery experiment?’”

With a little guidance from her lab mentor Tracey Day, Ph.D., and with plenty of her own innovation, Winkler developed an engaging drug discovery lab that will be replicated for dozens of students in Dehn’s classroom. “The BioQuest program helped me land a research job, so it’s exciting to think that my training led to a new lab that will engage more students in science,” Winkler said.

A surprising discoveryWinkler tested various plant extracts – moss, blackberry vine, even tomato leaf – for their ability to inhibit growth of three different bacterial species: E.coli, Bacillus megaterium (found in soil) and Mycobacterium smegmatis (a non-pathogenic cousin of tuberculosis). “My hypothesis was that one of the plant extracts would have some effect on inhibiting E.coli or B. megaterium growth, but probably not M. smegmatis.”

Her results yielded a surprising discovery: The moss sample significantly inhibited the growth of M. smegamtis. Winkler explained that, similar to M. tuberculosis (the bacteria that causes TB), M. smegmatis has a waxy, lipid-rich cell wall that creates a tough barrier for drugs to permeate. When her moss extract succeeded in inhibiting bacteria growth, researchers in Seattle BioMed’s tuberculosis labs and BioQuest program took interest.

Sherman’s lab hopes to reproduce these results and to test the moss sample on actual tuberculosis bacteria. Additionally, the BioQuest team is adding the moss extract to its tuberculosis latency experiments, where teens investigate TB-like bacterial responses to stress conditions involving low oxygen, changes in pH, starvation, and now the moss extract.

“My backyard moss won’t be the silver bullet that stops TB,” admits Winkler, “but this experience has given me a great deal of hope for discoveries that can be made when students, teachers and scientists work together and learn from each other.”

Training and education are inherent values of Seattle BioMed. Visit seattlebiomed.org and seattlebioquest.org to learn more about our training programs ranging from high school students to postdoctoral fellows.

Jessica Winkler

87

In sub-Saharan Africa, more than 300,000 babies with HIV die each year. Mother-to-child transmission of HIV is as high as 40 percent, and HIV-infected children develop AIDS and die faster in South Africa than those in developed countries.

Investigating infant immunity

Don Sodora, Ph.D., and members of his lab greet a mother and daughter at a clinic in South Africa.

For Heather Jaspan, Ph.D., a Seattle BioMed staff scientist who trained in the HIV lab of Don Sodora, Ph.D., and who also holds a research position at the University of Cape Town, the drive to better understand HIV transmission and disease progression bridges from professional to personal. “I grew up in South Africa near Soweto, a community very much like Khayelitsha where I work with an HIV clinic,” said Jaspan. “I also have an 11-month-old son of my own. He’s full of energy and smiles, but I know many mothers and children in South Africa are battling the HIV burden.”

Jaspan believes she has an important role to play in helping the Khayeltisha community achieve better health. Thanks to grants awarded from the Pediatric AIDS Foundation and others, Jaspan spent the last year investigating whether or not a vaccination against an entirely different disease is increasing the probability that HIV-exposed infants contract HIV and more quickly progress to AIDS.

The TB vaccine dilemmaBacille Calmette-Guerín (BCG) vaccine is given to infants at birth in South Africa to protect them from severe forms of tuberculosis. While the BCG vaccination prevents healthy infants from getting sick from TB, it can also result in disseminated TB in HIV-positive infants and increase the risk of HIV infection among HIV-exposed infants.

BCG is known to cause immune cells to be active and replicate faster, and infant immune systems respond differently to BCG than to other vaccines and infections. With a team of researchers including undergraduate Global Health Intern Tali Azenkot, Jaspan set out to examine the effect of BCG vaccination on HIV-exposed infants.

“We hypothesized that the routine immunization of infants with BCG contributes to generalized immune activation in HIV-exposed infants, resulting in skewed

immune responses to vaccines and infections and increased rates of disease progression in those infants that become HIV-infected,” said Jaspan.

During her summer internship – made possible by Seattle BioMed donors who invest in scientific training – Azenkot helped Jaspan test her hypothesis. “We assessed immune cells in infants from South Africa clinics to determine the impact of the timing of BCG vaccination on immune responses to TB and other vaccines,” explained Azenkot.

Jaspan knows their test results will provide key insights into the effect of BCG vaccination on HIV disease susceptibility and progression. “Results will also inform the optimal timing of BCG vaccination for HIV-exposed infants,” she said.

“I hope our research will help us better understand whether or not to give HIV-exposed infants the BCG vaccine. And if so, when,” Jaspan said. “Ultimately, a better TB vaccine and an effective HIV vaccine are needed.”

Invest in innovationSeattle BioMed donors who support

research and scientific training have

enabled dozens of students and

scientists to get the training and

funding they need to pursue innovative

research ideas like Jaspan’s. Learn how

you can help fund these projects, as

well as help other scientists launch

cutting-edge research aimed at tackling

the toughest global health issues. Visit

seattlebiomed.org/breakthrough-fund.

Heather Jaspan, Ph.D., with her son in South Africa.

109

Learn more about the journeys of women who work at or support Seattle BioMed because they believe that women’s health is global health. Hear their hopeful stories at seattlebiomed.org/breakthrough-fund.

Two talented business women have been incredibly generous in dedicating their time and energy to advancing Seattle BioMed’s mission — especially as it relates to women’s health. Members of the Board of Trustees Jane Hedreen, owner of children’s clothier Flora and Henri, and Kris Richey, vice president at Kinzer Real Estate Services, share their unique perspectives on why they’re champions for improved women’s health.

Jane Hedreen

What inspires you to elevate global health awareness?

Years ago I heard economist Jeffrey Sachs speak at Seattle BioMed’s annual fundraising event, Passport to Global Health Celebration. He was rattling off alarming statistics about the U.S. spending more money per day on the Pentagon than it spends in a year on global health. At that moment I knew that we, as an educated community, had an opportunity to shift that focus for the better. We needed to start acting on the burden of HIV/AIDS, malaria and TB — diseases that have a detrimental impact on the world economy — in the same way we act on other economic issues.

What connects you to Seattle BioMed’s mission?

At my business Flora and Henri, we look to make connections with communities where we can make a lasting difference in the lives of women and children. We have made a commitment to partner with positive impact manufacturers to benefit women and children in developing areas, while teaching trades and supporting a woman’s ability to garner an independent wage.

Hope among womenDid you know?

• Women’straditionalrolesasthecaretakersandbrokersofhealthfor theirfamiliesputthematanunfair riskofcontractinginfectiousdiseases.

• WomenwithHIVmaysoonoutnumbermenwiththedisease.

• Pregnancyreducesawoman’simmunitytomalaria,makingher morevulnerabletoillness,severeanemiaanddeath.

• Tuberculosisisthethirdleadingcause ofdeathworldwideamongwomen age15-44andthefourthleading causeofdeathofgirlsandyoung womeninlow-incomecountries.

• ScientistsatSeattleBioMedarediscoveringnewpreventionsandtreatmentsagainstHIV/AIDS,malaria, TBandotherdiseasesthatare particularlydangeroustowomen.

In many ways, Seattle BioMed’s mission is close to that of my own business. Whether by encouraging women within my own network to learn about global health, or by raising awareness for the women in our factory in Madagascar, I like to think I’m playing a small role in empowering women locally and globally to lead productive lifestyles for the betterment of themselves, their families and their communities.

Why is women’s health global health?

I remember Melinda Gates saying that no mother in Africa should have to choose which of her children gets to sleep under a bed net. I agree that is a choice no mother should have to make. As smart, passionate women, we can build a global health community in the most positive sense – one in which people from all social and economic backgrounds can come together to make a difference in the lives of others.

Kris Richey When did you discover your passion for improving global health? My passion for global health goes back to my college days when I studied science and my early career as a scientist in the biotech industry. I eventually moved into the real estate business, and in 2005 I was introduced to Seattle BioMed via a real estate project. I was intrigued by the Institute’s mission to end the threat of infectious disease, so it didn’t take me long to ask Seattle BioMed how I could be of help. Six years later, I’m on Seattle BioMed’s board and helping the organization raise awareness of global health and infectious disease research.

How can women improve global health?

At a networking event held specifically for women, a conversation sparked about some of the world’s toughest economic and social problems facing women and children today. I was struck by how little global health came into the conversation — it seemed that people were clued into the ramifications of poor health, but they weren’t really seeing infectious disease as a root cause.

Fortunately, that event was organized by Seattle BioMed as an opportunity to get women talking about the biggest barrier to global health — infectious disease. A diverse, energized group of women started making connections between infectious diseases and the declining health of women and children around the world, and began asking what they could do to make improvements.

I’m excited to help Seattle BioMed continue outreach to women who are motivated to raise awareness of the challenges facing women’s health and support for the hope offered by Seattle BioMed’s research.

Interested in learning more about ways infectious diseases impact women’s health? Visit seattlebiomed.org and sign up to receive our global health newsletters and to attend events.

Seattle BioMed Board Members Kris Richey (left) and Jane Hedreen.

1211

Animal Health and Veterinary Laboratories Agency, United Kingdom

Astellas Pharma Inc., Japan Australian National University, CanberraBiomedical Primate Research Centre, The Netherlands Centre Hospitalier Universitaire Vaudois, LausanneChristian de Duve Institute of Cellular Pathology,

Université Catholique de Louvain, Belgium Egerton University, Kenya ETH-Zurich (Swiss Federal Institute of Technology Zurich)Griffith University, Australia Guy’s Hospital, United Kingdom Foundation for Innovative New Diagnostics,

Switzerland Imperial College, London INOVIO, Norway Institute of Infectious Diseases and Molecular

Medicine, University of Cape TownInstitute of Parasitology, Czech Academy of Sciences,

Czech Republic Institut Pasteur, FranceInstitut Pasteur, Korea Institute of Protein Biochemistry, National Research

Council, Italy International AIDS Vaccine InitiativeInternational Center for Genetics and Biotechnology,

India International Centre for Diarrheal Disease Research,

Bangladesh Jawaharlal Nehru University, India K-RITH (KwaZulu-Natal Research Institute for

Tuberculosis and HIV)London School of Hygiene and Tropical Medicine,

United KingdomMahidol University, Bangkok, ThailandMcGill University, Canada Melbourne UniversityMorogoro Regional Hospital, Tanzania Nanomics Biosystems Pty Ltd, Australia National Institute of Infectious Diseases, Japan National Institute for Medical Research, LondonNational Institute for Medical Research, Tanzania National Institute of Public Health and the

Environment, The Netherlands National Research Council of Canada Novartis Institute of Tropical Diseases, Singapore Oxford University, United Kingdom

Bill & Melinda Gates FoundationBurroughs Wellcome FundFoundation for the National Institutes of HealthFred Hutchinson Cancer Research CenterImplicit Bioscience Ltd.Infectious Disease Research InstituteInstitute for Systems BiologyNational Institutes of HealthEunice Kennedy Shriver National Institute of Child

Health and Human DevelopmentFogarty International CenterNational Center for Research ResourcesNational Heart, Lung, and Blood Institute

Response Biomedical Corporation, Canada Ruhr-Universität Bochum, Germany Sokoine University, Tanzania Swiss Tropical and Public Health InstituteTriTryp Genome Consortium Tumaini University, Tanzania Unversidade Federal de São Paulo, Escola Paulista de

Medicina, Brazil Universitätsklinikum Charité Berlin, Germany University Hospitals Geneva, Switzerland University of Alberta University of AmsterdamUniversity of Antioquia, Colombia University of Buea, Cameroon University of Cambridge, United Kingdom University of Cape Town, South Africa University of Copenhagen and Rigshospitalet,

Denmark University of Dar es Salaam, Tanzania University of Dundee, ScotlandUniversity of Edinburgh, Scotland University of Glasgow, Scotland University of Heidelberg, Germany University of Nairobi, Kenya University of Osaka, Japan

University of Otago, New Zealand University of Queensland, Australia University of the Ryukyus, Japan University of Strausbourg, GermanyUniversity of the Witwatersrand, Johannesburg,

South AfricaUniversity of Tokyo, JapanVrije Universiteit, The Netherlands Walter and Eliza Hall Institute of Medical Research,

Australia Wellcome Trust Sanger Institute, United Kingdom

Aaron Diamond AIDS Research Center Antigen Discovery, Inc.AttoDX, Inc.Bill & Melinda Gates Foundation Boston University Brandeis University Broad Institute Brown University Medical School Buck Institute C3 Jian, Inc., Los Angeles California Institute for Medical Research California Institute of Technology California National Primate Research Center Centers for Disease Control & PreventionColumbia University Cornell University Drexel University Duke University Emory UniversityFred Hutchinson Cancer Research Center General Hospital Corporation (Massachusetts

General Hospital)Harborview Medical Center Harvard University Indiana University Infectious Disease Research Institute Institute for Systems Biology Johns Hopkins University Keck Graduate InstituteLa Jolla Institute of Allergy and Immunology Los Alamos National Laboratory Microsoft Research National Institute on Alcohol Abuse and Alcoholism

Intramural ProgramNational Institutes of Health New York University North Carolina State University Northwestern University Novartis Vaccines & DiagnosticsOregon Health & Science University Oregon National Primate Research Center Oregon State University PATH Pacific Northwest National Laboratory Portland Veterans Affairs Medical Center Quality Biological, Inc.

UNITED STATES

Rockefeller UniversitySaint Louis University Santa Clara Valley Medical Center Schering Plough Biopharma Scripps Research Institute Seattle Children’s HospitalSeattle Genetics Southwest National Primate Research Center,

San Antonio St. Jude’s Children’s Hospital, MemphisStanford University TB Control Program, Public Health -

Seattle-King County Texas A & M University Tulane National Primate Research Center Tulane University University of California, Berkeley University of California, Davis University of California, Los Angeles University of California, San Francisco University of Chicago University of Illinois, Chicago University of Iowa University of MarylandUniversity of Massachusetts, Worchester University of Medicine and Dentistry of New JerseyUniversity of Michigan

University of Missouri University of Nebraska University of North Carolina University of Oklahoma University of Oregon University of Pennsylvania University of Pittsburgh University of Rochester Medical Center University of San Diego University of Texas Health Science Center at

San Antonio University of Texas Southwestern Medical Center

at Dallas University of Virginia University of Washington U.S. Environmental Protection Agency Vanderbilt University J. Craig Ventner Institute Walter Reed Army Institute of Research Washington National Primate Research Center Yale University Yecuris CorporationYerkes National Primate Research Center, Atlanta

GRANTORS & CONTRACTORSNational Institute of Allergy and Infectious DiseasesNational Institute of Dental and Craniofacial ResearchNational Institute of Diabetes and Digestive and

Kidney DiseasesNational Institute of General Medical SciencesNew York UniversityOregon Health and Science UniversityPATHPaul G. Allen Family FoundationRhode Island HospitalRockefeller UniversityScience Applications International CorporationThe Scripps Research Institute

Sequella, Inc.Silver Family FoundationStanford UniversityU.S. Army Medical Research and Materiel CommandU.S. Department of Health and Human Services -

HRSAUnited States-Israel Binational Science FoundationUniversity of Cape TownUniversity of PennsylvaniaUniversity of Washington

INTERNATIONAL

Collaborators

1413

COUNCIL OF SCIENTIFIC ADVISORSRafi Ahmed, Ph.D. Director, Emory Vaccine Center

Clifton E. Barry, III, Ph.D. Senior Investigator, Chief, Tuberculosis Research Section, NIAID, NIH

Bennett (Ben) M. Shapiro, M.D. ChairDirector of Research, Retired, Merck Research Laboratories

Jeffrey V. Ravetch, M.D., Ph.D. Theresa and Eugene Lang Professor at the Rockefeller University; Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology

John W. Shiver, Ph.D. Vice President, Worldwide Basic Research Franchise; Head, Vaccines, Merck Research Laboratories

Mike Tyers, Ph.D. CH Waddington Chair in Systems Biology, University of Edinburgh; Director of Scottish Universities Life Sciences Alliance (SULSA)

Thomas E. Wellems, M.D., Ph.D. Chief, Malaria Genetics Section, NIAID, NIH

EMERITUS BOARDAlan Alhadeff

Margaret Allen, M.D.

Ellsworth Alvord, Jr, M.D.

Mark Benjamin, Sc.D.

J Paul Blake

Carol Bryan

Vince Bryan

Robert Bunting

Alice Burgess

John Creighton, Esq.

Andrew Dale

James Davie

Nancy Duncan

Bruce Easter

Janet Lane Eaton

Steve Gillis, Ph.D.

Harris Hoffman

James A. Johnson

John King

Alvin Kwiram, Ph.D.

Carol Lewis

Jilan Liu, M.D., M.H.A.

Katherine M. Lombardo

Gary McGlocklin

PRINCIPAL INVESTIGATORSAlan Aderem, Ph.D.

Institute Director*

John Aitchison, Ph.D. Full Member & Director Integrative Biology

Jerry Cangelosi, Ph.D. Affiliate Member

Nick Crispe, M.D., Ph.D. Full Member

Malcolm Gardner, Ph.D. Full Member

Christoph Grundner, Ph.D. Assistant Member

Helen Horton, Ph.D. Associate Member

Stefan Kappe, Ph.D. Full Member & Program Director

Peter Myler, Ph.D. Full Member

Marilyn Parsons, Ph.D. Full Member & Program Director

David Sherman, Ph.D. Full Member & Program Director

Joe Smith, Ph.D. Associate Member

Don Sodora, Ph.D. Associate Member

Leo Stamatatos, Ph.D. Full Member & Program Director

Ken Stuart, Ph.D. Full Member, President & Founder**

Kevin Urdahl, M.D., Ph.D. Assistant Member

Ruobing Wang, M.D., Ph.D. Associate Member

Theodore White, Ph.D. Full Member

SEATTLE BIOMED LEADERSPRINCIPAL SCIENTISTSSean Gray, Ph.D.

Andrew Oleinikov, Ph.D.

Noah Sather, Ph.D.

SENIOR SCIENTISTSPeter Askovich, M.D., Ph.D.

Jason Carnes, Ph.D.

Amy DeRocher, Ph.D.

Alan Diercks, Ph.D.

Mark Gilchrist, Ph.D.

Elizabeth Gold, M.D.

Xuguang Hu, Ph.D.

Heather Jaspan, Ph.D.

Bryan Jensen, Ph.D.

Kathleen Kennedy, Ph.D.

Vladimir Litvak, Ph.D.

Sebastian Mikolajczak, Ph.D.

Brian Oliver, Ph.D.

Stephen Ramsey, Ph.D.

Carrie Rosenberger, Ph.D.

Tige Rustad, Ph.D.

Ramsey Saleem, Ph.D.

Frank Schmitz, M.D., Ph.D.

Shahin Shafiani, Ph.D.

Ashley Vaughan, Ph.D.

Daniel Zak, Ph.D.

STAFF SCIENTISTSMarion Avril, Ph.D.

Samuel Danziger, Ph.D.

Shokrollah Elahi, Ph.D.

Shari Kaiser, Ph.D.

Jiangning Li, Ph.D.

Henning Mann, Ph.D.

Aleksandr Ratushnyy, Ph.D.

James Sissons, Ph.D.

Vincent Tam, Ph.D.

CLINICAL TRIALS INVESTIGATORSSara Healy, M.D., Clinical

Trial Investigator

Angela Talley, M.D., Lead Trials Investigator

AFFILIATE MEMBERSPeter Doherty, MVSc, Ph.D.

Patrick Duffy, M.D.

Rob Moritz, Ph.D.

Achim Schnaufer, Ph.D.

Rentala Madhubala, Ph.D.

MANAGEMENTAlan Aderem, Ph.D.

Institute Director*

Tom Blackwell, Director of Information Technology

Karen Blöchlinger, Ph.D. General Counsel

Randy Hassler, Chief Operations Officer

Kent Irwin, Director of Operations & Facilities

Eileen Murphy, Senior Program Manager

Kim Loveall Price, Interim Vice President of Advancement

Lee Schoentrup, Director of Communications

Ken Stuart, Ph.D. President & Founder**

Jeanine Willis, Director of Human Resources

Lynn Zimmerman, Director of Finance

BIOQUESTTheresa Britschgi,

Director of BioQuest

Peter Miller, J.D.

Susan Morgensztern

Peggy Morrow

Thomas O’Rourke

Judy Pigott

Gloria Pfeif

Erick Rabins

Thomas Ranken

Chuck Robertson

Gilbert Scherer

Ezra Teshome

Usha Varanasi, Ph.D.

Tom Waldron

Rick Weller, M.D., & H.

Michelle A. Williams, Sc.D.

Mary Williamson

James Woods, Ph.D.

Jeffrey Wortley

Louis Yaseen

Updated 10/2011

15

Lisa Meyr, Karen Blöchlinger, Ph.D., and Kent Irwin

16

This is a publication of Seattle BioMed’s Communications Department: Lee Schoentrup, director, and Jennifer Mortensen, specialist. Photo credits: Don Sodora, Ph.D., MaryMargaret Welch.

*Effective 1/12, President**Effective 1/12, President Emeritus & Founder

Dean Allen Chief Executive Officer McKinstry

Rosemary Barker Aragon Communications Advisory Group Chair Executive Director Pacific Hospital PDA

Jane A. Biddle, Ph.D. Science Education Advisory Group Chair Technology Transfer Consultant

Gregg Blodgett Community Volunteer

Maud Daudon* Immediate Past Chair CEO & President Seattle-Northwest Securities Corporation

Marlyn Friedlander Community Volunteer

Jane Hedreen* Development Committee Co-Chair Owner, Flora & Henri

Darryl Johnson* SecretaryFormer US Ambassador to Thailand & Lithuania

Alan Levy, Ph.D. Venture Partner, Medical Devices Frazier Healthcare Ventures

Neil McDonnell, PharmD Deputy Director of Strategy, Global Health Program Bill & Melinda Gates Foundation

Terrence R. Meersman Vice President, Programs Margaret A Cargill Foundation

Trevor Moody* Vice Chair President TM Strategic Advisors LLC

Todd Patrick* Chair President & CEO C3-Jian, Inc.

Christopher H. Porter, Ph.D. President Medical Genesis

Kris Richey Development Committee Co-Chair Vice President Kinzer Real Estate Services

Mike Stull* Treasurer & Finance Committee Chair Chief Financial Officer Clarisonic

Moya Vazquez* Board Operations & Governance Committee ChairCommunity Volunteer

Bryan White Managing Director & Chief Investment Officer BlackRock Alternative Advisors

Melissa Yeager Chief Operating Officer Cardeas Pharma

*Executive Committee

Fiscal years ending June 30 (dollars in thousands)SELECT F INANCIAL DATA

BOARD OF TRUSTEES

*Includes one-time contribution to support scientific expansion and leadership

Audited statements available upon request. Please e-mail connect@seattlebiomed.org.

Statements of financial position

2011 2010

Cash & investments $21,203,046 $19,037,896

Pledges receivable $3,484,055 $432,449

Other assets $7,683,610 $7,301,587

Property & equipment $10,170,785 $10,934,896

Total assets $42,541,496 $37,706,828

Accounts payable & accrued expenses $4,704,532 $4,593,542

Advances & deferred obligations $10,335,651 $9,686,105

Capital project debt $2,608,351 $3,481,384

Total liabilities $17,648,534 $17,761,031

Total net assets $24,892,962 $19,945,797

Statements of activities

2011 2010

Support & revenue

Government grants $27,858,893 $23,723,086

Private grants $12,599,217 $21,915,452

Contributions $7,737,172* $494,903

Educational program $99,442 $112,918

Investment & other income $3,395,006 $3,228,851

Total support & revenue $51,689,730 $49,475,210

Expenses

Research program $38,947,458 $43,820,173

Educational program $869,233 $933,110

Management & administrative $6,080,604 $5,153,655

Fundraising $845,270 $811,036

Total expenses $46,742,565 $50,717,974

Increase (decrease) in net assets $4,947,165 ($1,242,764)

1817

Revenue&support

2011

Contributions 15%

Other income 7%

Government grants 54%

Private Grants 24%

Budgetbyprogramarea

HIV/AIDS 21%

Emerging & Neglected

Diseases 35%

Malaria 33%

Tuberculosis 11%

2011

2011 DONOR HONOR ROLL

Founder’s Circle

$1,000,000+Bill & Melinda Gates Foundation

$50,000+Dean & Vicki Allen/McKinstry Co. Charitable Foundation

Todd & Julie Patrick

Silver Family Foundation

$25,000+Anonymous

Byron & Alice Lockwood Foundation

Gilbert Scherer & Marlyn Friedlander

$10,000+Drs. Alan Aderem & Kathy Barker

The Paul G. Allen Family Foundation

Anonymous

Gregg & Jane Blodgett

The Crystal Family Foundation in memory of Norman S. Crystal

Jane Hedreen & David Thyer

KeyBank Foundation

Jones Lang LaSalle

Becky Roberts

Lucie Robitaille & Antoine Leblond

Charles Spear Charitable Trust

The Team Trio Fund in memory of Dr. David Clemetson

Vulcan Inc.

Wells Fargo Insurance Services

We Work For Health

Pacesetters’ Circle

$5,000+Perry, Christine & Cooper Atkins

Betty Bottler

Concur Technologies, Inc.

The Crowley Family

Maud & Marc Daudon

Firland Foundation

Gilead Sciences, Inc.

Richard & Elizabeth Hedreen

Mike & Liz Hilton

KeyBank National Association

Kinzer Real Estate Services

Lease Crutcher Lewis

The Lucky Seven Foundation

Mark Malamud & Susan Hautala

Trevor J. Moody & Laura Hernon

Petrizzo Bond, Inc.

Kris Richey

Moya Vazquez

The Adam J. Weissman Foundation

$2,500+Anonymous (3)

BNBuilders, Inc.

Drs. Jane A. Biddle & Kenneth B. Seamon

ClearPoint

James & Sarah Davie

Frazier Family Foundation

GLY Construction

Group Health Cooperative

Betsy & Eric Hentz/Mallet Inc.

Margot Kenly & Bill Cumming

Life Technologies

Moss Adams LLP

Perkins+Will

Gloria Pfeif

Michael Podlin

Christopher & Kathryn Porter

Gordon & Gretchen Raine

Redman Family Foundation

Stephen Rothrock & Tessa Keating

H. Jon & Judith Runstad

Russell Investments

Ronald & Sara Seubert

Drs. Ken Stuart & Julie McElrath

Daniel D. Syrdal

Tommy Bahama Group

VLST Corporation

John & Teresa White

Wilson Sonsini Goodrich & Rosati

Melissa Yeager & Cory Van Arsdale

ZymoGenetics, Inc.

$1,000+Bill & Janette Adamucci

John & Leslie Aitchison

Alexandria Real Estate Equities Inc.

Lisa & Michael Anderson

Rosemary Barker Aragon & Luis Aragon

Mark Ashida & Lisbet Nilson

The Baden Family

Kristin & Steven Beaulieu

Bruce & Ann Blume

David & Madeleine Brenner

Rich & Janice Bristol

Victoria Buker

Wayne & Jody Burns

Randy Campadore

Clark Nuber P.S.

Sally Collins & Chris Warth

Paul & Debbie Cressman

Steve Davis & Bob Evans

Bruce Easter & Cynthia Faubion

Deborah Elvins

Nathan & Lisa Every

Carolynn & Hal Ferris

First Tech Credit Union

JoAnn & Barry Forman

Greg Foster

Kerry Fowler & Jan Gray

Malcolm J. Gardner & Ruobing Wang

William & Mimi H. Gates, Sr.

Kevin & Ann Harrang

Hudson Bay Insulation

Pam & Kim Kaiser

R. Hans & Kelly Kemp

ChiEun Kim

Chris Larson & Julia Calhoun

Alan & Sharon Levy

Michael & Julie Metzger

Morningside Foundation

NBBJ

Nyhus Communications

PATH

Jacques Peschon

Mary Pigott

Audi Purnaveja

Wendy & Bill Rabel

Erick & Marta Rabins & Family

Pradip Rathod, Ph.D.

The Reuben B. Robertson Foundation

Lawrence J. Roseman

Will & Lee Schoentrup

Mike & Alex Shimizu

Margaret & Hunt Stockwell

Mike & Sandra Stull

Ezra & Yobi Teshome

Steven & Karen van Til

John Wechkin & Erinn McIntyre

Carl Weissman

Mary Williamson & Kurt Kiefer

Jeanine Willis & Eric Freyberg

Tachi & Leslie Yamada

Mariann & Kirk Zylstra

Continuedonpage21

2019

Hope starts with you.“It takes an incredible body of people to bring about the change in infectious diseases that an organization like Seattle BioMed is looking to make. Any person, in any professional discipline, has a contribution to give.” — Jill Scott, associate counsel for Seattle BioMed

The people with the most influence on global health are people like you. You have invested your time and money, and you have joined us on our journey, to end the threat of infectious disease. Individuals, foundations and corporations that imagine a world free from this burden play a significant role in enabling Seattle BioMed to expand research programs, recruit innovative scientists and form powerful collaborations that will ultimately lead to a healthier world.

We spread our hope through curiosity, inspiration and dedication, and we ask you to continue your investment in discovery research. Thank you for bringing us closer to our vision of a world free from infectious disease.

2011 DONOR HONOR ROLL (continued)

Continued...

2221Thankyouforsupportingusinour35thanniversaryyear.

Supporters

$500+Eve & Chap AlvordAnonymousSean BarnesTracy BennettBonnie BerkTom BlackwellKaren BlöchlingerAnna BranRobert & Theresa BritschgiJayne CoeBeth & Marc DroppertDiane DusseauBarbara Feasey & Bill BryantJoe FugereSaul & Devorah GamoranTimothy S. Girvin & Dawn ClarkBrad & Sarah GrayJoe W. & Denise HarrisRandy & Melanie HasslerSteve & Amy HumphreysKathlyn HusonSusan HutchisonKent & Louise IrwinDarryl & Kathleen JohnsonMaryann Jordan & Joe McDonnellLaird Norton Company LLCSusan Lammers & Walter EuyangChristina & Jim LockwoodMcGraw-HillDorcas McLennanGlen & Alison MillimanMortensen Family FundPeter Myler & Alexa AllenAnthony OgilvieThomas O’Riordan & Caroline StamatoMarilyn ParsonsDean PettersonAnne PfeifPatricia PfeifThe Pew Charitable TrustsSally QuyRegina Rabinovich & Franco PiazzaRobert L. & Virginia R. Rausch

Jill RosenastScott & Kerry RosenkranzSabey CorporationSalal Credit UnionDrs. Susan Scanlan & Anthony LoSidiya SchoppertJill & Tristan ScottSeattle Seahawks & Seattle SoundersJoan SedikSellen ConstructionGenie ShethChristine SimonAlan Smith & Christie SnyderSpeckman Law GroupHelen R. StusserSandhya SubramanianRon & Hannah TildenDavid & Lolly VictorThe Doctors WhitesideKatherine & Richard WolniewiczMarion Woodfield & Marc WeinbergAnn P. WyckoffJane Zalutsky & Mark Kantor

$350Jack & Sarah AitchisonMichelle Anderson & Paul OlivierJoe & Anne BaldwinHallock Beals & Susan CarpenterElisabeth BodalJerry Cangelosi & Gemma BorgKen & Sharon ColemanWill & Ginelle CousinsMark & Deb DavisSteve & Erin EirschelePaul & Vanessa FaulknerAmy HaroonKen & Cathi HatchTom & Sydney HodgeHelen Horton & Donald CarterKate Joncas & David TraylorKaren Jones & Erik RasmussenCraig & Danna KinzerMarc & Charleen KretschmerPeter & Melba LancasterNeil & Merri Ann McDonnell

Nicole & Robert MooneyAlex & Nayla MorcosEileen & Barry MurphyJoanie ParsonsCathy PerryDavid Powers & Amy ChasanovUdo & Carla ReichMaria K. ReyesMike SchaeferDr. Jaime SepulvedaJennifer & Kirk StephensErik StromTim & Barbara TaskerEstelle N. ThyerGuy ThyerToni & Michael TibbitsKate TuneNico Van der MeulenJoan WrightEugene Yang

$250+Benjamin O. AbeSusan AdlerBruce & Joann AmundsonTad & Cindy AndersonRobert S. AngelAnonymous (4)John & Linda BowersJeanne BrovoldEvan BrownIgor CestariColeman HarrisJulius Debro & Darlene ConleyJennifer DodsonShannon DowneyNancy & Alan EmsleyQuentin Ertel & Carolyn KennedyElaine ErvinMeredith & Steve EveristRob GoldbergDiane Grover & Mark KibbeyDouglas Haas & Helena Hillinga-HaasM. Elizabeth HalloranToni HatzakisFrances Ann HayesHamilton Hazelhurst & Pam BekinsAda Healey

Scott & Emily HighleymanKaren M. Hill & Sheldon N. RosenBart HoberechtPaul & Robin HollandArthur E. HoltzKaty Horan & Dan FilonowichMary HuLawton HumphreyElizabeth JamesStefan Kappe & Dasha Li KappeAngela KuoAlice LinJosé Lopez, M.D.Minkyung & Marco LoweLisa & Nathaniel MeyrSebastian MikolajczakNate MilesTracy MitchellBruce & Joanne Montgomery, M.D.Ralph MunroDavid & Julie ParkJudith PierceJohn PrideBridget RaffertyKathleen RydarEric & Caroline SandersonRocky Sheldon & Ellen FitzgeraldBryan ShermanJoseph & Leia SmithMarian SmithDon SodoraOtto H. Spoerl & Lyne ErvingMichael SwiftCarlos TruebaJames TuckerDavid TuttDrs. Kevin Urdahl & Maria BuschTina VlasatyKimberly Vora & David MoxonDoug & Stacey WaddellWashington Biotechnology &

Biomedical AssociationKatherine WeybrightRon Wilkowski & Kyla FairchildAnn H. WilliamsPaul & Kathryn WohnoutkaBernice WuethrichJon & Stephanie de Vaan

The 2011 donor list includes new pledges, outright gifts of cash and stock, pledge payments, and in-kind donations received from July 1, 2010, through June 30, 2011. Donors of $1,000 and above are listed on the donor wall at Seattle BioMed.

Each of our donors is important to us. Please e-mail connect@seattlebiomed.org with any omissions or errors.

MissionEvery day, we strive to eliminate the world’s most devastating infectious diseases.

VisionWe envision a world where people live free from the threat of infectious disease.

About Seattle BioMedSeattle BioMed is the largest, independent, non-profit research institute in the U.S. focused solely on the world’s most devastating infectious diseases. More than 360 strong, we are dedicated to reducing human suffering and saving lives by converting knowledge into solutions.

Our research is the foundation for new vaccines, drugs and diagnostics that will benefit those who need our help most: the 14 million who will otherwise die each year from infectious diseases.

Disease FocusEmerging & Neglected Diseases African sleeping sickness Amebiasis Chagas’ disease Fungal infections Leishmaniasis Toxoplasmosis

Malaria

Tuberculosis

Viral Diseases HIV/AIDS Influenza

Hope starts with you.

Printed on recycled paper.

© 2011 Seattle Biomedical Research Institute.

307 Westlake Avenue North, Suite 500 – Seattle, Washington 98109-5219 USA

Phone: 206.256.7200 – Fax: 206.256.7229 - seattlebiomed.org

Seattle Biomedical Research Institute is a 501(c)3 nonprofit organization. Federal tax ID #91-0961784.

On the cover: Ramsey Saleem, Ph.D., Crystal Dinh and Claire Gendrin, Ph.D.